The obesity drug craze is entering its next p...

As once-vocal inflation hawk Kevin Warsh prepares for his first meeting as the central bank’s chair, prices are now rising at a sharp 4% rate. In this week’s Viewsroom, Breakingviews columnists debate how he can square the obvious remedy with President Trump’s rate-cut demands. B ...  Show more

The $113 bln oil major is reeling after it parted company with the leader of its board, Albert Manifold. In this Viewsroom podcast, Breakingviews columnists discuss the company’s governance missteps, and why the latest drama makes it vulnerable to a takeover. Breakingviews: BP ch ...  Show more

Listen to the first episode of our new podcast. Host Carmel Crimmins and China bureau chief Kevin Krolicki discuss recent moves by the US to impose tariffs on China’s hot industry – EVs. What is protectionism versus good local policy, how have we arrived at this point, and what d ...  Show more

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ...  Show more

Riots rage in New Caledonia, as France approves changes to voting rules in the French territory. President Biden’s top economic adviser – Lael Brainard – joins the Reuters World News podcast for an interview, as the US hits China with steep tariffs. Plus, Secretary of State Anton ...  Show more

Passengers are left shaken after severe turbulence hit a Singapore Airlines flight. Eli Lilly’s diabetes drug wins approval in China, intensifying weight loss drugmakers’ competition in the Asian market. And a Kenyan police deployment to Haiti to help combat gang violence is immi ...  Show more